by Truveta staff | May 17, 2023 | News
We are excited to announce the expansion of the Truveta community to include new life science partners, including Reprieve Cardiovascular and SK Life Science, joining previously announced pioneers Pfizer, Boston Scientific Corporation, and Alpine Immune Sciences. We...
by Truveta Research | Sep 15, 2022 | Research, Research Insights
COVID-19 impacted communities disproportionately [1]. Especially in the early days of the pandemic, countless reports of inequitable access to treatments and treatment pathways brought to light existing and new disparities in health outcomes [2]. Addressing health...
by Truveta Research | Jun 21, 2022 | Research, Research Insights
Long COVID is a term used to describe patients with returning or sustained symptoms following a SARS-CoV-2 infection. Physicians and researchers have described numerous post COVID-19 complications, including cardiovascular, coagulation and hematologic,...
